SecBot SecBot
8-K ·Filed Jun 10, 2026

IDYA

IDEAYA Biosciences, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001193125-26-265833
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

The offering provides a large cash runway for IDEAYA's pipeline programs, reducing near-term financing risk. However, the 12%+ dilution combined with no disclosed revenue or earnings improvement for the quarter is a negative signal for existing holders. Monitor the company's next pipeline update for trial data that could justify the expanded share count. The 60-day lock-up expiration in early August 2026 may create an overhang if insiders sell into the market.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$28.84
T+0 close · Jun 10, 2026 · via day close
Latest settled
+38.21%
T+60 · $39.86
Vs SPY
+33.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $28.84entry
  2. T+1 · 5mo ago +0.49%α −0.06% · $28.98
  3. T+5 · 5mo ago +8.39%α +7.96% · $31.26
  4. T+20 · 4mo ago +29.26%α +27.37% · $37.28
  5. T+60 · 2mo ago +38.21%α +33.82% · $39.86
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

IDEAYA Biosciences completed a follow-on public offering on June 10, 2026, selling 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares, generating net proceeds of approximately $323.6 million. This is a material dilutive event for a $2.5B market cap company. Stockholders' equity per share is diluted by this issuance, although the ~$323.6M in new cash extends the cash runway for clinical development.

Key Facts

  • Sold 7,222,225 shares of common stock at $27.00/share and pre-funded warrants for 5,555,576 shares at $26.9999/warrant.
  • Net proceeds of approximately $323.6 million after underwriting discounts and estimated expenses.
  • Pre-funded warrants have an exercise price of $0.0001 per share, meaning investors effectively bought common stock exposure at the offering price minus a de minimis exercise price.
  • Underwriters' option for 1,666,669 additional shares was exercised in full.
  • The offering is dilutive, 7.2 million new common shares (~12%+ dilution pre-warrants exercise) against a pre-offering share base estimated from a $2.5B market cap at $27/share (~92.6M shares outstanding pre-offering), resulting in ~8% dilution from shares alone, plus potential further dilution from warrants.
  • Lock-up agreements restrict insider sales for 60 days post-prospectus date.

Financial Impact

Company raised ~$323.6M in net cash. Dilution: 7.2M new shares + 5.6M warrant shares represent roughly 12-14% total potential dilution to existing holders.

dilutioncashshares outstandingequity per share

Risk Factors

  • Significant dilution from new shares and pre-funded warrants (~12-14% total potential dilution).
  • No corresponding revenue or earnings catalyst disclosed in this filing.
  • 60-day lock-up ends in August, creating potential selling pressure from insiders.
  • For a pre-commercial biotech, clinical trial failures would magnify the impact of a larger share base.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-265833
Document: d110954dex41.htm0001193125-26-265833
Document: d110954d8k.htm0001193125-26-265833
Document: d110954dex51.htm0001193125-26-265833
Document: 0001193125-26-265833-index-headers.html0001193125-26-265833
Document: 0001193125-26-265833-index.html0001193125-26-265833
Document: 0001193125-26-265833.txt0001193125-26-265833

Track record

13 reports on IDYA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  2. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  3. Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
  4. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
  6. Jun 10, 202622w ago 8-K Bearish 6/10 Viewing Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
  7. Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
  8. Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
  10. May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (9h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026